ERBB2 and non-small cell lung carcinoma: Encouragingly, the recent advance of ADCs such as T-DM1 [4] and T-DXd [5, 30], TKIs such as pyrotinib [7, 31] or poziotinib [10] showed inspiring antitumor activity in HER2-mutated NSCLC in phase II trials, which made HER2 mutation a druggable target.